RSS Feeds
Search

Out-licensing

Development of Drug for Vitiligo Treatment Using Histamine_DONGGUK UNIVERSITY

Korea Health Industry Development Institute
The core technology of Dongguk University is to provide anti-vitiligo agents from bee venom.

Full description

 

Technology Platform

The core technology of Dongguk University is to provide promising anti-vitiligo agents from bee venom. The bee venom extracts exhibit anti-vitiligo activities by distinctly various actions such as hyperpigmentation, enhanced proliferation and migration of melanocytes, production of melanin, and so on.

Background and unmet needs: Vitiligo is a chronic disorder that causes depigmentation in patches of skin. It occurs when the melanocytes, the cells responsible for skin pigmentation which are derived from the neural crest, die or are unable to function. Although a cause of vitiligo has not been understood, there is some evidence suggesting it is caused by a combination of autoimmune, genetic, and environmental factors. It is also common in people with thyroid disorders. The population incidence worldwide is considered to be less than 1 percent.

Bee venom is a bitter colorless liquid, which causes local inflammation and acts as an anticoagulant. The venom is produced in the abdomen of worker bees from a mixture of acidic and basic secretions. Bee venom therapy is used by some as a treatment for rheumatism and joint diseases due to its anticoagulant and anti-inflammatory properties.

Discovery and Achievements: Anti-vitiligo agents of Dongguk University have been developed on the basis of findings that the bee venom may induce proliferation of melanocytes and have anti-inflammatory activities. It is very difficult to isolate an active ingredient from bee venom, but several components were identified from bee venom. Of them, histamine, particularly H2 group, is very effective in production of melanin, proliferation and migration of melanocytes and formation of dendritic branches.

Development status

Early Stage

Patent information

 

Country

Patent, Publication or Appln. No.

Status

Description

Korea

10-2009-0022877

Pending

Pharmaceutical composition for treatment of vitiligo containing histamine

Korea

10-2007-0003866

Granted

Compositions for Treating Vitiligo Comprising Bee Venom and Method for Screening Inhibitors against the Pigmentation Induced by Bee Venom

Korea

10-2005-0005317

Granted

Method for Screening Responsiveness to Drugs Effectivein Treatment or Prevention of Vitiligo and Method forPrognosis of Vitiligo

Korea

10-2005-0012288

Granted

A pharmaceutical composition comprising retinoid for prevention and treatment of vitiligo

Korea

10-2007-0006652

Granted

Method for Screening Materials for Preventing or Treating Vitiligo

Korea

10-2007-0104238

Pending

Polynucleotides for diagnosis of vitiligo and a diagnostic method of vitiligo using thereof

Korea

10-2009-0022937

Pending

Composition for Preventing or Treating of Obesity, Dyslipidemia, Fatty Liver or Insulin Resistance Syndrome Comprising Camphene as Active Ingredients

Korea

10-2009-0028030

Pending

Composition for Preventing or Treating of Obesity, Dyslipidemia, Fatty Liver or Insulin Resistance Syndrome Comprising Camphor as Active Ingredients

Related reports

Licensing contact

Yong U KIM
Business Development Manager
Health Technology Transfer Center

Contact directly

Company details

Korea Health Industry Development Institute

KHIDI, provides various services on technology transfer. KHIDI will license and commercialise several technologies of KHIDI's client companies via collaboration with overseas partners.

View profile

Related technologies

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us